Notable Upgrades: Corcept Therapeutics (CORT), Impax Laboratories (IPXL), Tiffany & Co. (TIF), Inogen (INGN), Actavis plc (ACT)

Analysts at Piper Jaffray are out with a report this morning upgrading shares of Corcept Therapeutics Incorporated (CORT) with a ‘Overweight‘ from ‘Neutral‘ rating. The firm raised its price target for the company to $9.00 from $2.50.

Corcept Therapeutics Inc. shares are currently priced at 24.62x next year’s forecasted earnings. Ticker has a forward P/E of 24.66 and t-12 price-to-sales ratio of 12.85. EPS for the same period is ($0.31).

In the past 52 weeks, shares of Menlo Park California-based firm have traded between a low of $1.69 and a high of $4.49 and are now at $3.95. Shares are down 17.00% year-over-year ; up 12.33% year-to-date.

Analysts at Piper Jaffray upgraded their rating on the shares of Impax Laboratories Inc. (IPXL). In a research note published on Wednesday, the firm lifted the name with a ‘Overweight‘ from ‘Neutral‘ rating.

On valuation measures, Impax Laboratories Inc. shares are currently priced at 51.54x this year’s forecasted earnings compared to the industry’s (3.47)x earnings multiple. Ticker has a PEG and forward P/E ratio of 1.41 and 19.53, respectively. Price/Sales for the same period is 4.45 while EPS is $0.81. Currently there are 4 analysts that rate IPXL a ‘Buy’, 9 rate it a ‘Hold’. No analyst rates it a ‘Sell’. IPXL has a median Wall Street price target of $40.00 with a high target of $49.00.

Tiffany & Co. (TIF) was raised to ‘Overweight‘ from ‘Neutral‘ at Atlantic Equities on Wednesday.

TIF is up $0.72 at $84.16 on heavy volume. Midway through trading Wednesday, 1.40 million shares of Tiffany & Co. have exchanged hands as compared to its average daily volume of 1.41 million shares. The stock ranged in a price between $83.30-$85.44 after having opened the day at $84.97 as compared to the previous trading day’s close of $83.44.

In the past 52 weeks, shares of New York-based company have traded between a low of $82.75 and a high of $110.60. Shares are down 9.38% year-over-year and 21.92% year-to-date.

Inogen, Inc. (INGN) was upgraded to ‘Buy‘ from ‘Hold‘ by Stifel analysts on Wednesday. The broker set its price target on the stock to $45.

INGN is currently printing a higher than average trading volume with the issue trading over 399K shares, compared to the average volume of 147K. The stock began trading this morning at $35.00 to currently trade 9.02% higher from the prior days close of $33.92. On an intraday basis it has gotten as low as $35.00 and as high as $37.30.

Inogen Inc. shares are priced at 77.20x this year’s forecasted earnings. The name has a t-12 price-to-sales ratio of 6.12. EPS for the same period registers at $0.48.

INGN shares have advanced 10.85% in the last 4 weeks and 36.44% in the past three months. Over the past 5 trading sessions the stock has gained 1.74%.

The Goleta California-based company, which is currently valued at $688.86 million, has a median Wall Street price target of $35.00 with a high target of $36.00. Inogen Inc. is up 73.95% year-over-year, compared with a 9.42% gain in the S&P 500.

Actavis plc (ACT) was reiterated a ‘Buy’ by Citigroup analysts on Wednesday. The broker also raised its price target on the stock to $360 from $325, implying 11% expected return.

ACT shares recently gained $6.38 to $293.98. In the past 52 weeks, shares of Little Island, Ireland-based company have traded between a low of $184.71 and a high of $298.23. Shares are up 37.82% year-over-year and 11.73% year-to-date.

Be the first to comment

Leave a Reply

Your email address will not be published.


*